APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2024 FINANCIAL OUTLOOKApyxMedical2025-12-12T18:06:50+00:00March 21, 2024|Read More
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS ON MARCH 21, 2024ApyxMedical2025-12-12T18:07:17+00:00March 4, 2024|Read More
APYX MEDICAL CORPORATION ANNOUNCES RENUVION TO BE FEATURED IN EDUCATIONAL SESSIONS AT THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) SCIENTIFIC MEETINGApyxMedical2025-12-12T18:07:44+00:00February 21, 2024|Read More
APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED CLINICAL PUBLICATION EVALUATING THE SAFETY OF RENUVION FOLLOWING LIPOSUCTION IN MULTIPLE AREAS OF THE BODYApyxMedical2025-12-12T18:08:11+00:00January 22, 2024|Read More
APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2023 REVENUE RESULTSApyxMedical2025-12-12T18:12:35+00:00January 8, 2024|Read More
APYX MEDICAL CORPORATION APPOINTS MATTHEW HILL AS CHIEF FINANCIAL OFFICERApyxMedical2025-12-12T18:13:02+00:00November 28, 2023|Read More
APYX MEDICAL CORPORATION ANNOUNCES NEW DEBT FACILITY WITH PERCEPTIVE ADVISORSApyxMedical2025-12-12T18:58:20+00:00November 9, 2023|Read More
APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOKApyxMedical2025-12-12T18:58:55+00:00November 9, 2023|Read More
APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN NOVEMBERApyxMedical2025-12-12T18:59:25+00:00November 7, 2023|Read More
APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON NOVEMBER 9, 2023ApyxMedical2025-12-12T18:59:53+00:00October 2, 2023|Read More
APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND REAFFIRMS FULL YEAR 2023 FINANCIAL OUTLOOKApyxMedical2025-12-12T19:00:21+00:00August 10, 2023|Read More
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON AUGUST 10, 2023ApyxMedical2025-12-12T19:00:50+00:00June 29, 2023|Read More
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) CLEARANCE FOR THE RENUVION MICRO HANDPIECEApyxMedical2025-12-12T19:01:32+00:00June 14, 2023|Read More
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOKApyxMedical2025-12-12T19:02:02+00:00May 11, 2023|Read More
RENUVION RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTIONApyxMedical2025-12-12T19:02:46+00:00May 2, 2023|Read More
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURINGApyxMedical2025-12-12T19:03:25+00:00April 28, 2023|Read More
